Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.

Mol, Clifford D; Fabbro, Doriano; Hosfield, David J

Mol, Clifford D; Fabbro, Doriano; Hosfield, David J.

Affiliation

Mol CD; Syrrx Inc, La Jolla, CA 92121, USA. clifford.mol@syrrx.com

Curr Opin Drug Discov Devel ; 7(5): 639-48, 2004 Sep.

Article in En | MEDLINE | ID: mdl-15503866

Subject(s)

Molecular Conformation; Piperazines/chemistry; Protein Kinase Inhibitors/chemistry; Pyrimidines/chemistry; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Design; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Molecular Structure; Piperazines/pharmacology; Piperazines/therapeutic use; Protein Kinase Inhibitors/pharmacology; Protein Kinase Inhibitors/therapeutic use; Pyrimidines/pharmacology; Pyrimidines/therapeutic use

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Piperazines / Pyrimidines / Protein Kinase Inhibitors / Molecular Conformation Type of study: Prognostic_studies Limits: Humans Language: En Year: 2004 Type: Article

Search on Google

XML

PubMed Links